Arbutus Biopharma Corporation (ABUS)
Largest Insider Buys in Sector
ABUS Stock Price History Chart
ABUS Stock Performance
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Insider Activity of Arbutus Biopharma Corporation
Over the last 12 months, insiders at Arbutus Biopharma Corporation have bought $0 and sold $111,487 worth of Arbutus Biopharma Corporation stock.
On average, over the past 5 years, insiders at Arbutus Biopharma Corporation have bought $0 and sold $509,906 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $13,900 was made by HENRIQUES RICHARD C JR (director) on 2015‑08‑24.
List of Insider Buy and Sell Transactions, Arbutus Biopharma Corporation
| 2024-08-14 | Sale | director | 8,846 0.0048% | $3.69 | $32,637 | 0.00% | ||
| 2024-02-02 | Sale | Interim President & CEO | 10,164 0.0057% | $2.31 | $23,504 | +40.34% | ||
| 2024-02-02 | Sale | Chief Scientific Officer | 9,982 0.0056% | $2.31 | $23,083 | +40.34% | ||
| 2024-02-02 | Sale | Chief Financial Officer | 9,593 0.0054% | $2.31 | $22,184 | +40.34% | ||
| 2024-02-02 | Sale | Chief Medical Officer | 4,358 0.0024% | $2.31 | $10,078 | +40.34% | ||
| 2021-12-01 | Sale | Chief Scientific Officer | 200,000 0.218% | $5.09 | $1.02M | -44.14% | ||
| 2021-02-09 | Sale | Chief Business Officer | 20,000 0.0239% | $5.00 | $100,000 | -25.28% | ||
| 2020-12-14 | Sale | Chief Business Officer | 40,000 0.0439% | $5.00 | $200,032 | -29.51% | ||
| 2020-07-23 | Sale | Chief Business Officer | 20,000 0.0203% | $5.01 | $100,200 | -46.45% | ||
| 2018-08-13 | Sale | Chief Scientific Officer | 4,250 0.0076% | $9.51 | $40,436 | -60.00% | ||
| 2018-07-11 | Sale | Chief Scientific Officer | 10,000 0.017% | $10.00 | $100,000 | -61.98% | ||
| 2018-07-09 | Sale | Chief Scientific Officer | 10,000 0.0183% | $8.91 | $89,060 | -53.41% | ||
| 2018-07-06 | Sale | Chief Scientific Officer | 10,000 0.0166% | $8.45 | $84,500 | -55.27% | ||
| 2018-07-05 | Sale | Chief Scientific Officer | 10,000 0.0167% | $8.40 | $84,000 | -54.73% | ||
| 2018-07-03 | Sale | Chief Scientific Officer | 10,000 0.0174% | $8.00 | $80,000 | -50.24% | ||
| 2017-10-03 | Sale | Chief Scientific Officer | 20,000 0.0392% | $8.00 | $160,000 | -21.85% | ||
| 2017-08-15 | Sale | Chief Scientific Officer | 60,000 0.1079% | $3.70 | $222,000 | +51.33% | ||
| 2015-08-24 | director | 2,000 0.004% | $6.95 | $13,900 | -39.25% |
Insider Historical Profitability
| McElhaugh Michael J. | Interim President & CEO | 1504793 0.7941% | $3.58 | 0 | 4 | |
| Sofia Michael J. | Chief Scientific Officer | 1485121 0.7837% | $3.58 | 0 | 10 | |
| HASTINGS DAVID C | Chief Financial Officer | 181907 0.096% | $3.58 | 0 | 1 | |
| Sims Karen | Chief Medical Officer | 125542 0.0663% | $3.58 | 0 | 1 | |
| MANCHESTER KEITH S | director | 46069 0.0243% | $3.58 | 0 | 1 | |
| HENRIQUES RICHARD C JR | director | 1000 0.0005% | $3.58 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Whitefort Capital Management Lp | $33.18M | 6.82 | 12.86M | -2.54% | -$864,067.80 | 21.68 | |
| BlackRock | $26.84M | 5.51 | 10.4M | +0.14% | +$36,943.02 | <0.01 | |
| Morgan Stanley | $22.78M | 4.68 | 8.83M | +26.43% | +$4.76M | <0.01 | |
| Kairos Capital Management Lp | $20.23M | 4.16 | 7.84M | -13.27% | -$3.1M | 9.69 | |
| The Vanguard Group | $15.45M | 3.17 | 5.99M | -0.02% | -$2,518.08 | <0.0001 | |
| Woodline Partners LP | $10.5M | 2.16 | 4.07M | -13.76% | -$1.68M | 0.09 | |
| Hudson Bay Capital Management LP | $9.08M | 1.87 | 3.52M | -14.96% | -$1.6M | 0.06 | |
| Adage Capital Partners Gp L L C | $7.74M | 1.59 | 3M | New | +$7.74M | 0.01 | |
| FourWorld Capital Management | $7.74M | 1.59 | 3M | +175.06% | +$4.93M | 11.09 | |
| Geode Capital Management | $7.63M | 1.57 | 2.96M | +5.01% | +$364,315.37 | <0.01 | |
| State Street | $6.74M | 1.38 | 2.61M | +8.98% | +$555,035.38 | <0.0001 | |
| Citadel Advisors LLC | $5.15M | 1.06 | 2M | +3.2% | +$159,562.67 | <0.01 | |
| Advisor Group Holdings Inc | $3.53M | 0.73 | 1.37M | 0% | +$0 | 0.01 | |
| Centiva Capital | $3.49M | 0.72 | 1.35M | -4.78% | -$175,027.18 | 0.11 | |
| Northern Trust | $2.73M | 0.56 | 1.06M | -1.09% | -$29,971.86 | <0.0001 | |
| Corbin Capital Partners, L.P. | $2.2M | 0.45 | 853,304 | New | +$2.2M | 15.21 | |
| Boothbay Fund Management LLC | $1.58M | 0.32 | 612,277 | +34.97% | +$409,314.51 | 0.05 | |
| Wellington Management Company | $1.16M | 0.24 | 451,305 | New | +$1.16M | <0.0001 | |
| Kennedy Capital Management Inc | $1.13M | 0.23 | 436,506 | +12.72% | +$127,103.65 | 0.02 | |
| BNY Mellon | $1.05M | 0.22 | 407,625 | -10.77% | -$126,943.80 | <0.0001 | |
| Saba Capital Management, L.P. | $963,527.00 | 0.2 | 373,460 | New | +$963,527.00 | 0.02 | |
| Charles Schwab | $875,175.00 | 0.18 | 339,215 | -2.9% | -$26,168.95 | <0.0001 | |
| Bank of Montreal | $872,431.00 | 0.18 | 334,265 | -5.11% | -$46,979.96 | <0.0001 | |
| Nuveen | $758,922.00 | 0.16 | 294,156 | 0% | +$0 | <0.0001 | |
| Millennium Management LLC | $624,907.00 | 0.13 | 242,212 | -84.25% | -$3.34M | <0.0001 | |
| Citigroup | $585,371.00 | 0.12 | 226,888 | +965.95% | +$530,455.70 | <0.0001 | |
| Goldman Sachs | $450,739.00 | 0.09 | 174,705 | +38.01% | +$124,136.73 | <0.0001 | |
| RhumbLine Advisers | $439,779.00 | 0.09 | 170,460 | +3.54% | +$15,056.61 | <0.0001 | |
| Fidelity Investments | $427,872.00 | 0.09 | 165,842 | +0.3% | +$1,284.84 | <0.0001 | |
| UBS | $347,844.00 | 0.07 | 134,823 | -3.68% | -$13,281.86 | <0.0001 | |
| American Century Investments | $325,632.00 | 0.07 | 126,214 | +53.17% | +$113,040.08 | <0.0001 | |
| Clear Harbor Asset Management | $299,953.00 | 0.06 | 116,261 | -16.52% | -$59,339.93 | 0.03 | |
| Susquehanna Fundamental Investments Llc | $265,544.00 | 0.06 | 102,924 | New | +$265,544.00 | 0.01 | |
| Lighthouse Investment Partners, LLC | $255,562.00 | 0.05 | 99,055 | New | +$255,562.00 | 0.02 | |
| Two Sigma | $252,623.00 | 0.05 | 97,916 | -51.96% | -$273,270.72 | <0.0001 | |
| AllianceBernstein | $247,783.00 | 0.05 | 96,040 | 0% | +$0 | <0.0001 | |
| Simplex Trading Llc | $227,000.00 | 0.05 | 88,130 | -15.63% | -$42,061.84 | 0.01 | |
| Barclays | $230,000.00 | 0.05 | 89,186 | -58.7% | -$326,891.10 | <0.0001 | |
| JPMorgan Chase | $227,381.00 | 0.05 | 88,132 | -23.68% | -$70,555.40 | <0.0001 | |
| Royal Bank of Canada | $188,000.00 | 0.04 | 73,146 | -31.78% | -$87,574.49 | <0.0001 | |
| Deutsche Bank | $187,973.00 | 0.04 | 72,858 | +9.49% | +$16,290.07 | <0.0001 | |
| Bank of America | $176,634.00 | 0.04 | 68,463 | -25.54% | -$60,598.86 | <0.0001 | |
| Group One Trading | $170,195.00 | 0.04 | 65,967 | +802.17% | +$151,330.02 | <0.01 | |
| MetLife Investment Management | $159,630.00 | 0.03 | 61,872 | +4.9% | +$7,458.79 | <0.01 | |
| American International Group | $161,093.00 | 0.03 | 62,439 | -0.85% | -$1,382.88 | <0.01 | |
| Invesco | $153,608.00 | 0.03 | 59,538 | +5.05% | +$7,391.70 | <0.0001 | |
| LMR PARTNERS LLP | $154,800.00 | 0.03 | 60,000 | 0% | +$0 | <0.01 | |
| The Manufacturers Life Insurance Company | $137,081.00 | 0.03 | 53,132 | +1.85% | +$2,489.71 | <0.0001 | |
| Cowen Group | $129,000.00 | 0.03 | 50,000 | 0% | +$0 | <0.01 | |
| Voya Investment Management LLC | $115,855.00 | 0.02 | 44,905 | -20.23% | -$29,381.06 | <0.0001 |